Health ProductsDear Healthcare Professional Letter

Archived - Implantable Pacemakers - Advisories, Warnings and Recalls for Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Medical Device
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Guidant Canada Corporation.

Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on certain Implantable Pacemakers

January 21, 2006

URGENT MEDICAL DEVICE SAFETY INFORMATION & CORRECTIVE ACTION

Subject: Two subsets of PULSAR® MAX, PULSAR, DISCOVERY®, MERIDIAN®, PULSAR MAX II, DISCOVERY II, VIRTUS® Plus II, INTELIS® II and CONTAK® TR implantable pacemakers

Dear Health Care Professional,

This letter is intended to inform you of important safety information regarding the potential for loss of therapy due to hermetic seal degradation in two subsets of PULSAR MAX, PULSAR, DISCOVERY, MERIDIAN, PULSAR MAX II, DISCOVERY II, VIRTUS Plus II, INTELIS II and CONTAK TR pacemakers. This letter advises physicians about potential unanticipated device behaviors and is intended to limit adverse events.

Guidant previously communicated information regarding hermetic seal degradation in a subset of the above pacemakers in a physician letter dated July 18, 2005. Since that time, the projected rate of occurrence has increased for this advisory population. In addition, Guidant has identified a second population of devices outside of the advisory population that may also be susceptible to hermetic seal degradation. Our records indicate that you have implanted or are monitoring patients with devices from one or both of these populations. Health Canada classified the July 18, 2005 physician letter as a Priority I recall and has indicated this communication may be classified as an expansion of that recall.

Summary of the July 18, 2005 Physician Letter

As described in the July 18, 2005 letter to physicians, Guidant's Quality System determined that a hermetic sealing component utilized in 78,000 devices manufactured between November 25, 1997 and October 26, 2000 may experience a gradual degradation, resulting in a higher than normal moisture content within the pacemaker case late in the device's service life. This may lead to one or more of the following device behaviors:

  • Premature battery depletion resulting in loss of telemetry and/or loss of pacing output without warning
  • Inappropriate accelerometer function (if programmed ON), resulting in:
    • Sustained pacing at the programmed Maximum Sensor Rate (MSR)
    • Lack of appropriate accelerometer rate response during activity
  • Appearance of a reset warning message upon interrogation
  • Inappropriate early display of replacement indicators

Important Clinical Notes:

  1. While interrogation of the device may identify devices that have already experienced this failure mode, Guidant has not identified any test that will predict if a device will exhibit this failure mode in the future.
  2. While inappropriate accelerometer function has been observed in 45% of the failures reported to date, it cannot be relied upon as an early indicator of this failure mode.
  3. While disabling accelerometer function will mitigate inappropriate MSR pacing, moisture penetration can still cause the other behaviors described above, including loss of output.

Advisory Population Update

Observed rate of occurrence:* Guidant has further defined the advisory population as 77,500 devices manufactured between October 27, 1997 and October 26, 2000. Since the July 18, 2005 physician letter, Guidant has identified 76 additional devices that may have exhibited hermetic seal degradation. Seventy-one (71) of those devices have been confirmed through laboratory analysis to have exhibited hermetic seal degradation; two devices are currently undergoing analysis; three devices may have experienced hermetic seal degradation but were not returned to Guidant for confirmation. A total of 145 reported incidents out of 77,500 devices represents a rate of occurrence of 0.19%. It is estimated that 16,000 devices in this population remain implanted worldwide and an estimated 800 devices remain implanted in Canada.

Clinical Implications: As of January 9, 2006, Guidant has confirmed a total of 71 reports of loss of pacing output, including ten patients who experienced syncope and two instances of cardiac arrest with resuscitation. Loss of pacing output has also been associated with reports of presyncope requiring hospitalization. Guidant has received 65 reports of Maximum Sensor Rate (MSR) pacing associated with hermetic seal degradation. Sustained MSR pacing has been associated with one report of myocardial infarction, two reports of possible development of heart failure, and five reports of shortness of breath that could be indicative of heart failure. As reported in the July 18, 2005 physician letter, one patient whose device exhibited sustained MSR pacing was admitted to the hospital with multiple health issues and later expired. It is unknown if the device experienced hermetic seal degradation as the device was not returned and hermetic seal degradation could not be confirmed.

Projected rate of occurrence:† Based on further investigation and laboratory analysis of returned devices, Guidant's projected rate of occurrence for reported events within the remaining lifetime of active devices is now estimated to be between 0.31% and 0.88%, which has increased from the July 18, 2005 estimate of between 0.17% and 0.51%.

Second Population

Since our July 18, 2005 physician letter, Guidant has identified a second population of 54,000 devices manufactured between October 19, 1998 and December 5, 2000 that are at risk of hermetic seal degradation, though at a much lower rate than the advisory population. Guidant identified this second population after investigating reports of five pacemakers outside the advisory population exhibiting clinical behaviors similar to those described in the July 18, 2005 physician letter. At the time devices in the second population were assembled, hermetic sealing components susceptible to gradual degradation were mistakenly mixed with a much larger group of non-susceptible components. Within the second population of 54,000 devices, Guidant has identified by model number and date-of-manufacture approximately 2,500 devices with susceptible components, but is unable to identify susceptible devices by serial number.

Observed rate of occurrence:* As of January 9, 2006, two devices in the second population have been confirmed to have exhibited hermetic seal degradation; three devices may have exhibited hermetic seal degradation but have not been returned to Guidant for confirmation. A total of five reported incidents out of 54,000 represents a rate of occurrence of 0.009%. It is estimated that 19,300 devices in this second population remain implanted worldwide.

Clinical Implications: As of January 9, 2006, Guidant has confirmed two reports of loss of pacing output, including one patient who required hospitalization for presyncope and chest pain. Three devices exhibited high rate MSR pacing and remain implanted.

Projected rate of occurrence:† If a device in the second population has a susceptible component, it is subject to a risk of hermetic seal degradation equal to that of the original population. However, because devices with a susceptible component cannot be specifically identified and are distributed among the 54,000 devices in the second population, the projected rate of occurrence for reported events within the second population is substantially lower than the projected rate of occurrence for the original advisory population. For the remaining lifetime of active devices, the projected rate of occurrence for reported events within the second population is estimated to be between 0.02% and 0.06%.

* The number of actual clinical incidents may be greater than the number reported to Guidant.

† Assumes that devices remain implanted through normal replacement indicators. Predictive modeling is inherently uncertain due to its dependence on the device age distribution of reported events and resultant statistical approximations and assumptions.

Recommendations

Original advisory population

Guidant's original patient management recommendations from the July 18, 2005 physician letter remain unchanged. When determining the most appropriate patient management option, physician should consider the unique needs of each individual patient, including pacemaker dependency, as well as the age and remaining service life of the pacemaker. Guidant recommends that physicians reassess their patients in light of the increased projected rate of occurrence.

  • Consider replacing devices for pacemaker-dependent patients.
  • Advise patients to seek attention immediately if they notice a prolonged rapid heart rate, experience syncope or lightheadedness, or have new or increased symptoms of heart failure.
  • Select a suitable MSR setting, given the rare possibility that inappropriate sustained pacing at MSR can occur, or
  • Consider programming the accelerometer OFF to prevent inappropriate sustained pacing at MSR and potential clinical consequences of sustained rapid heart rate.
  • Consider increasing the frequency of programmer follow-ups. This increases the likelihood of detecting a failure that has already occurred, but does not guarantee that the device will not exhibit this failure mode in the future. At each patient follow-up:
    • Evaluate for the clinical behaviors described above.
    • Evaluate battery status indicator ("gas gauge") for signs of early or rapid depletion between sequential follow-up visits.
    • Evaluate the accelerometer rate response (for devices with this feature).
Accelerometer Status Evaluation Criteria
ON
  • Look for inappropriate MSR pacing or pacing higher than the programmed lower rate limit while the patient is at rest.
  • Look for lack of rate response with activity (i.e., isometrics, short hall walk).
OFF Temporarily program the accelerometer ON and evaluate as described above.
  • Consider increasing the frequency of transtelephonic monitoring to detect inappropriate sustained MSR pacing and/or loss of pacing output.

Second/New Population

Physicians should consider the above recommendations while taking into account the lower projected rate of occurrence and the unique needs of each individual patient, including pacemaker dependency, when making patient management decisions for patients in the second population.

Warranty Supplement Program

Guidant's warranty supplement program, subject to certain conditions, provides a no cost replacement device. The program is available through June 30, 2006 and is applicable to both populations.

Model Numbers Affected

Both populations include the following model numbers:

Device Family Model Device Family Model
* Devices not sold in Canada
DISCOVERY II 0481, 0981, 1184, 1186, 1187, 1283, 1284, 1285, 1286 PULSAR MAX 1170, 1171, 1270
DISCOVERY 1174, 1175, 1273, 1274, 1275 PULSAR MAX II 1180, 1181, 1280
PULSAR 0470, 0870, 0970, 0972, 1172, 1272 MERIDIAN 0476, 0976, 1176, 1276
INTELIS II* 1483, 1484, 1485, 1384, 1385, 1349, 1499 CONTAK TR 1241
VIRTUS Plus II* 1380, 1480    

A list of second population devices specific to your clinic is enclosed. A device model/serial number look-up/search tool is also available at http://www.guidant.com in the Product Safety Information section.

Guidant recognizes the impact of this communication on both you and your patients, and wants to reassure you that patient safety remains Guidant's primary concern. As always, if you have any questions regarding this communication, please contact your local Guidant representative or Guidant Technical Services at 1.800.CARDIAC (227-3422).

Guidant Canada
505 Apple Creek Blvd., Unit 4
Markham, Ontario L3R 5B1
CANADA
Phone: (905) 947-5800 or 1-800-268-4487
Fax: (905) 947-5830

Any suspected adverse incident can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675

The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738

Sincerely,

original signed by

Scott Kadwell
Country Manager, Cardiac Rhythm Management
Guidant Canada Corporation

Attachment 1

Addendum

Communication Summary

Population Advisory Population Advisory Population - Updated Second Population
* Predictive modeling is inherently uncertain, and assumes that the devices remain implanted throughout normal replacement indicators.
** In one report, a patient whose device exhibited sustained MSR pacing was admitted to the hospital with multiple health issues and later expired. It is unknown if the device experienced hermetic seal degradation as the device was not returned and hermetic seal degradation could not be confirmed.
Communication Method Physician Letter Physician Letter  
Date July 18, 2005 January 20, 2006  
Affected Population A bounded subset manufactured between October 27, 1997 and October 26, 2000 A bounded subset manufactured between October 19, 1998 and December 5, 2000
Worldwide Devices Distributed 78,000 77,500 54,000
Remaining Implanted Devices in the US (approximate) 18,000 10,800 11,700
Cumulative Reported Incidents 69 145 5
Reported Incidence Rate 0.09% 0.19% 0.009%
Projected Incidence Rate* 0.17% to 0.51% 0.31% to 0.88% 0.02% to 0.06%
Cumulative Reported Deaths** 0 0 0
Root Cause A hermetic sealing component may experience gradual degradation, resulting in a higher than normal moisture content within the pacemaker case late in the device's service life. This may lead to one or more inappropriate behaviors, exhibited individually or in combination.
Health Canada Classification Priority I recall Priority I recall Health Canada has indicated this communication may be classified as an expansion of the July 2005 Priority I recall.
Warranty Supplement Program Effective through 06/30/2006 Effective through 06/30/2006 Effective through 06/30/2006
Recommendations See physician communication July 18, 2005 Unchanged. Additionally Guidant recommends that physicians reassess their patients in light of the increased projected rate of occurrence. Physicians should consider the July 2005 communication recommendations while taking into account the lower projected rate of occurrence and the unique needs of each individual patient, including pacemaker dependency, when making patient management decisions.

Attachment 2

URGENT MEDICAL DEVICE SAFETY INFORMATION & CORRECTIVE ACTION

Fax-back Confirmation Form

Device Family Model Device Family Model
* Devices not sold in Canada
DISCOVERY II 0481, 0981, 1184, 1186, 1187, 1283, 1284, 1285, 1286 PULSAR MAX 1170, 1171, 1270
DISCOVERY 1174, 1175, 1273, 1274, 1275 PULSAR MAX II 1180, 1181, 1280
PULSAR 0470, 0870, 0970, 0972, 1172, 1272 MERIDIAN 0476, 0976, 1176, 1276
INTELIS II* 1483, 1484, 1485, 1384, 1385, 1349, 1499 CONTAK TR 1241
VIRTUS Plus II* 1380, 1480    

Please complete this form and return to:
Guidant Canada Regulatory
Fax: 1-800-390-3043

Institution:

Address:

City:

Province:

Postal Code:

This will confirm receipt of the Urgent Medical Device Safety Information Notice dated January 21, 2006 on the above-mentioned PULSAR® MAX, PULSAR, DISCOVERY®, MERIDIAN®, PULSAR MAX II, DISCOVERY II, VIRTUS® Plus II, INTELIS® II, AND CONTAK® TR

Signed:

Date:

Name:(Please print or type)

Title:(Please print or type)

Department:

Telephone:

Fax:

Internal Use Only

Confirmed by

Date

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime